Related Experiment Video
Updated: Jun 26, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in
Niresh Hariparsad1, Xiaoyan Chu, Jocelyn Yabut
1Department of Drug Metabolism and Pharmacokinetics, Merck & Co, Rahway, NJ 07065, USA. niresh_hariparsad@merck.com
Abstract:
Chromatin immunoprecipitation (ChIP) studies were conducted in human hepatocytes treated with rifampicin in order to identify new pregnane-X receptor (PXR) target genes. Genes, both previously known to be involved and not known to be involved in drug disposition, with PXR response elements (PXREs) located upstream, within or downstream from their potentially associated genes, were identified. Validation experiments identified several new drug disposition genes with PXR binding sites. Of these, only CYP4F12 demonstrated increased binding in the presence of rifampicin. The role of PXR in the basal and inductive response of CYP4F12 was confirmed in hepatocytes in which PXR was silenced. We also assessed the association of PXR-coactivators and -corepressors with known and newly identified PXREs. Both PXR and the steroid receptor coactivator (SRC-1) were found to bind to PXREs in the absence of rifampicin, although binding was stronger after rifampicin treatment. We observed promoter-dependent patterns with respect to the binding of various coactivators and corepressors involved in the regulation of CYP4F12, CYP3A4, CYP2B6, UGT1A1 and P-glycoprotein. In conclusion, our findings indicate that PXR is involved in the regulation of CYP4F12 and that PXR along with SRC1 binds to a broad range of promoters but that many of these are not inducible by rifampicin.
Insights
This study identified new drug disposition genes regulated by the pregnane-X receptor (PXR). While PXR and SRC-1 bind many gene promoters, only CYP4F12 showed increased binding with rifampicin.
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Background:
- The pregnane-X receptor (PXR) is a key regulator of drug metabolism and disposition.
- Identifying novel PXR target genes is crucial for understanding drug response variability.
Purpose of the Study:
- To identify new drug disposition genes regulated by PXR using chromatin immunoprecipitation (ChIP).
- To investigate the role of PXR in the regulation of CYP4F12 and its interaction with coactivators/corepressors.
Main Methods:
- Chromatin immunoprecipitation (ChIP) in human hepatocytes treated with rifampicin.
- Identification and validation of PXR response elements (PXREs).
- PXR silencing experiments and assessment of coactivator/corepressor binding.
Main Results:
- Several new drug disposition genes with PXR binding sites were identified.
- CYP4F12 demonstrated increased PXR binding in the presence of rifampicin, confirmed by silencing studies.
- PXR and SRC-1 bind to a broad range of promoters, but not all are rifampicin-inducible.
Conclusions:
- PXR plays a significant role in regulating CYP4F12 expression.
- PXR and SRC-1 exhibit broad promoter binding, with context-dependent coactivator/corepressor interactions.
- Rifampicin induces PXR binding to specific target genes, highlighting its role in drug metabolism regulation.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cell Specific Gene Expression
RNA Polymerase II Accessory Proteins
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
